Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We are downgrading our recommendation on ConocoPhillips (COP - Analyst Report) to Underperform from Neutral, on the back of disappointing first-quarter earnings. Financial leverage also deteriorated with a higher debt-to-total capital ratio and lower cash balance.
ConocoPhillips’ first quarter earnings and revenue came in below the Zacks Consensus Estimate. The earnings of the Exploration and Production segment fell year over year mainly on account of reduced volumes, higher taxes and lower natural gas prices. Additionally, a dip in refining margins during the quarter pulled down the Refining and Marketing segment profits.
In May 2012, ConocoPhillips completed the spin-off of its refining/sales business into a separate, independent and publicly traded company Phillips 66 (PSX - Snapshot Report). This has left ConocoPhillips with a less diversified business. As a result, the business risk profile of the reorganized ConocoPhillips is weaker than that of the pre-spin-off company.
Moreover, given the substantial investment required to augment upstream operations, any strategic change in the composition of ConocoPhillips’ assets will involve considerable capital expenditures, in addition to the planned outlay. This may be significantly burdensome for the company’s future cash flows and put pressure on its already strained balance sheet.
Having already divested $20.2 billion of non-strategic assets last year and $1.1 billion in the first quarter of 2012, and plans to offload $10 billion worth of properties this year, the company’s output is likely to be affected with production shrinking further.
Our bearish investment thesis on ConocoPhillips also takes into consideration ConocoPhillips’ sensitivity to changes in the crude oil price, as well as geopolitical risks associated with international operations and operational challenges. In fact, the pessimism around the stock is well reflected through its estimate revisions.
Currently, the Zacks Consensus Estimate for ConocoPhillips’ second-quarter 2012 earnings stands at $1.49 per share, down 38% year over year. Of the 8 estimates, 2 moved downward in the last 30 days, while no upward revision was witnessed. For 2012, the Zacks Consensus Estimate is pegged at $6.40 per share, down 27% year over year.
Given these concerns, we expect ConocoPhillips to perform below its peers and industry levels in the coming months. As such, we see little reason for investors to own the stock. Our long-term Underperform recommendation is supported by a Zacks #5 Rank (short-term Strong Sell rating).
Get the full Analyst Report on COP - FREE
Get the full Snapshot Report on PSX - FREE